Risk factors and mechanisms of non-alcoholic steatohepatitis

Pathophysiology

Volumn 15, Issue 2, 2008, Pages 109-114

  Rivera, Chantal A ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Cardiovascular disease; Diabetes; Liver disease; Obesity; Steatohepatitis

Indexed keywords

INTERLEUKIN 6; LEPTIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

ADIPOCYTE; ADIPOSE TISSUE; ARTICLE; COMORBIDITY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE SEVERITY; ENDOTOXEMIA; ETHNICITY; FAT INTAKE; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RACE DIFFERENCE; RISK FACTOR; SEX DIFFERENCE; SLEEP APNEA SYNDROME;

EID: 48349114960     PISSN: 09284680     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pathophys.2008.04.003     Document Type: Article

References (69)

1. Tarantino G., Saldalamacchia G., Conca P., and Arena A. Non-alcoholic fatty liver disease: further expression of the metabolic syndrome. J. Gastroenterol. Hepatol. 22 (2007) 293-303
2. Rashid M., and Roberts E.A. Nonalcoholic steatohepatitis in children. J. Pediatr. Gastroenterol. Nutr. 30 (2000) 48-53
3. McCullough A.J. Update on nonalcoholic fatty liver disease. J. Clin. Gastroenterol. 34 (2002) 255-262
4. Ogden C.L., Flegal K.M., Carroll M.D., and Johnson C.L. Prevalence and trends in overweight among US children and adolescents, 1999-2000. JAMA 288 (2002) 1728-1732
5. Harnois F., Msika S., Sabate J.M., Mechler C., Jouet P., Barge J., and Coffin B. Prevalence and predictive factors of non-alcoholic steatohepatitis (NASH) in morbidly obese patients undergoing bariatric surgery. Obes. Surg. 16 (2006) 183-188
6. Ong J.P., Elariny H., Collantes R., Younoszai A., Chandhoke V., Reines H.D., Goodman Z., and Younossi Z.M. Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients. Obes. Surg. 15 (2005) 310-315
7. Park J.W., Jeong G., Kim S.J., Kim M.K., and Park S.M. Predictors reflecting the pathological severity of non-alcoholic fatty liver disease: comprehensive study of clinical and immunohistochemical findings in younger Asian patients. J. Gastroenterol. Hepatol. 22 (2007) 491-497
8. Bjorntorp P. Body fat distribution, insulin resistance, and metabolic diseases. Nutrition 13 (1997) 795-803
9. Bjorntorp P. Regional patterns of fat distribution. Ann. Intern. Med. 103 (1985) 994-995
10. Couillard C., Bergeron N., Prud'homme D., Bergeron J., Tremblay A., Bouchard C., Mauriege P., and Despres J.P. Gender difference in postprandial lipemia: importance of visceral adipose tissue accumulation. Arterioscler. Thromb. Vasc. Biol. 19 (1999) 2448-2455
11. Singh D.K., Sakhuja P., Malhotra V., Gondal R., and Sarin S.K. Independent predictors of steatohepatitis and fibrosis in asian indian patients with non-alcoholic steatohepatitis. Dig. Dis. Sci. (2007)
12. Sobhonslidsuk A., Jongjirasiri S., Thakkinstian A., Wisedopas N., Bunnag P., and Puavilai G. Visceral fat and insulin resistance as predictors of non-alcoholic steatohepatitis. World J. Gastroenterol. 13 (2007) 3614-3618
13. Cheung O., Kapoor A., Puri P., Sistrun S., Luketic V.A., Sargeant C.C., Contos M.J., Shiffman M.L., Stravitz R.T., Sterling R.K., and Sanyal A.J. The impact of fat distribution on the severity of nonalcoholic fatty liver disease and metabolic syndrome. Hepatology 46 (2007) 1091-1100
14. Kroh M., Liu R., and Chand B. Laparoscopic bariatric surgery: what else are we uncovering? Liver pathology and preoperative indicators of advanced liver disease in morbidly obese patients. Surg. Endosc. 21 (2007) 1957-1960
15. Weisberg S.P., McCann D., Desai M., Rosenbaum M., Leibel R.L., and Ferrante Jr. A.W. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. 112 (2003) 1796-1808
16. Gerhardt C.C., Romero I.A., Cancello R., Camoin L., and Strosberg A.D. Chemokines control fat accumulation and leptin secretion by cultured human adipocytes. Mol. Cell. Endocrinol. 175 (2001) 81-92
17. Kern P.A., Saghizadeh M., Ong J.M., Bosch R.J., Deem R., and Simsolo R.B. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J. Clin. Invest. 95 (1995) 2111-2119
18. Kern P.A., Ranganathan S., Li C., Wood L., and Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am. J. Physiol. Endocrinol. Metab. 280 (2001) E745-E751
19. Feingold K.R., Hardardottir I., and Grunfeld C. Beneficial effects of cytokine induced hyperlipidemia. Z. Ernahrungswiss 37 Suppl. 1 (1998) 66-74
20. Greenberg A.S., Nordan R.P., McIntosh J., Calvo J.C., Scow R.O., and Jablons D. Interleukin 6 reduces lipoprotein lipase activity in adipose tissue of mice in vivo and in 3T3-L1 adipocytes: a possible role for interleukin 6 in cancer cachexia. Cancer Res. 52 (1992) 4113-4116
21. Hirosumi J., Tuncman G., Chang L., Gorgun C.Z., Uysal K.T., Maeda K., Karin M., and Hotamisligil G.S. A central role for JNK in obesity and insulin resistance. Nature 420 (2002) 333-336
22. Fantuzzi G., and Faggioni R. Leptin in the regulation of immunity, inflammation, and hematopoiesis. J. Leukoc. Biol. 68 (2000) 437-446
23. Ikejima K., Honda H., Yoshikawa M., Hirose M., Kitamura T., Takei Y., and Sato N. Leptin augments inflammatory and profibrogenic responses in the murine liver induced by hepatotoxic chemicals. Hepatology 34 (2001) 288-297
24. Kern P.A., Di Gregorio G.B., Lu T., Rassouli N., and Ranganathan G. Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression. Diabetes 52 (2003) 1779-1785
25. Kirchgessner T.G., Uysal K.T., Wiesbrock S.M., Marino M.W., and Hotamisligil G.S. Tumor necrosis factor-alpha contributes to obesity-related hyperleptinemia by regulating leptin release from adipocytes. J. Clin. Invest. 100 (1997) 2777-2782
26. Ikejima K., Takei Y., Honda H., Hirose M., Yoshikawa M., Zhang Y.J., Lang T., Fukuda T., Yamashina S., Kitamura T., and Sato N. Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat. Gastroenterology 122 (2002) 1399-1410
27. Saxena N.K., Ikeda K., Rockey D.C., Friedman S.L., and Anania F.A. Leptin in hepatic fibrosis: evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice. Hepatology 35 (2002) 762-771
28. Honda H., Ikejima K., Hirose M., Yoshikawa M., Lang T., Enomoto N., Kitamura T., Takei Y., and Sato N. Leptin is required for fibrogenic responses induced by thioacetamide in the murine liver. Hepatology 36 (2002) 12-21
29. Yang S.Q., Lin H.Z., Lane M.D., Clemens M., and Diehl A.M. Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 2557-2562
30. Jaskiewicz K., Rzepko R., and Sledzinski Z. Fibrogenesis in fatty liver associated with obesity and diabetes mellitus type 2. Dig. Dis. Sci. (2007)
31. Canbakan B., Senturk H., Tahan V., Hatemi I., Balci H., Toptas T., Sonsuz A., Velet M., Aydin S., Dirican A., Ozgulle S., and Ozbay G. Clinical, biochemical and histological correlations in a group of non-drinker subjects with non-alcoholic fatty liver disease. Acta Gastroenterol. Belg. 70 (2007) 277-284
32. Bell D.S., and Allbright E. The multifaceted associations of hepatobiliary disease and diabetes. Endocr. Pract. 13 (2007) 300-312
33. Beymer C., Kowdley K.V., Larson A., Edmonson P., Dellinger E.P., and Flum D.R. Prevalence and predictors of asymptomatic liver disease in patients undergoing gastric bypass surgery. Arch. Surg. 138 (2003) 1240-1244
34. Hyogo H., Yamagishi S., Iwamoto K., Arihiro K., Takeuchi M., Sato T., Ochi H., Nonaka M., Nabeshima Y., Inoue M., Ishitobi T., Chayama K., and Tazuma S. Elevated levels of serum advanced glycation end products in patients with non-alcoholic steatohepatitis. J. Gastroenterol. Hepatol. 22 (2007) 1112-1119
35. Yamagishi S., Nakamura K., Matsui T., Takeuchi M., and Minodronate. a nitrogen-containing bisphosphonate, is a promising remedy for treating patients with diabetic retinopathy. Med. Hypotheses 66 (2006) 273-275
36. Fehrenbach H., Weiskirchen R., Kasper M., and Gressner A.M. Up-regulated expression of the receptor for advanced glycation end products in cultured rat hepatic stellate cells during transdifferentiation to myofibroblasts. Hepatology 34 (2001) 943-952
37. Tanne F., Gagnadoux F., Chazouilleres O., Fleury B., Wendum D., Lasnier E., Lebeau B., Poupon R., and Serfaty L. Chronic liver injury during obstructive sleep apnea. Hepatology 41 (2005) 1290-1296
38. Savransky V., Bevans S., Nanayakkara A., Li J., Smith P.L., Torbenson M.S., and Polotsky V.Y. Chronic intermittent hypoxia causes hepatitis in a mouse model of diet-induced fatty liver. Am. J. Physiol. Gastrointest. Liver Physiol. 293 (2007) G871-G877
39. Savransky V., Nanayakkara A., Vivero A., Li J., Bevans S., Smith P.L., Torbenson M.S., and Polotsky V.Y. Chronic intermittent hypoxia predisposes to liver injury. Hepatology 45 (2007) 1007-1013
40. Zamora-Valdes D., and Mendez-Sanchez N. Experimental evidence of obstructive sleep apnea syndrome as a second hit accomplice in nonalcoholic steatohepatitis pathogenesis. Ann. Hepatol. 6 (2007) 281-283
41. Browning J.D., Szczepaniak L.S., Dobbins R., Nuremberg P., Horton J.D., Cohen J.C., Grundy S.M., and Hobbs H.H. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40 (2004) 1387-1395
42. Giday S.A., Ashiny Z., Naab T., Smoot D., and Banks A. Frequency of nonalcoholic fatty liver disease and degree of hepatic steatosis in African-American patients. J. Natl. Med. Assoc. 98 (2006) 1613-1615
43. Caldwell S.H., Harris D.M., Patrie J.T., and Hespenheide E.E. Is NASH underdiagnosed among African Americans?. Am. J. Gastroenterol. 97 (2002) 1496-1500
44. Solga S.F., Clark J.M., Alkhuraishi A.R., Torbenson M., Tabesh A., Schweitzer M., Diehl A.M., and Magnuson T.H. Race and comorbid factors predict nonalcoholic fatty liver disease histopathology in severely obese patients. Surg. Obes. Relat. Dis. 1 (2005) 6-11
45. Tikkanen M.J., and Nikkila E.A. Regulation of hepatic lipase and serum lipoproteins by sex steroids. Am. Heart J. 113 (1987) 562-567
46. Williams C.M. Cardiovascular risk factors in women. Proc. Nutr. Soc. 56 (1997) 383-391
47. Kobayashi J., Maruyama T., Watanabe H., Kudoh A., Tateishi S., Sasaki T., Murano S., and Watanabe M. Gender differences in the effect of type 2 diabetes on serum lipids, pre-heparin plasma lipoprotein lipase mass and other metabolic parameters in Japanese population. Diabetes Res. Clin. Pract. 62 (2003) 39-45
48. Carr M.C., Ayyobi A.F., Murdoch S.J., Deeb S.S., and Brunzell J.D. Contribution of hepatic lipase, lipoprotein lipase, and cholesteryl ester transfer protein to LDL and HDL heterogeneity in healthy women. Arterioscler. Thromb. Vasc. Biol. 22 (2002) 667-673
49. Lemieux S., Prud'homme D., Bouchard C., Tremblay A., and Despres J.P. Sex differences in the relation of visceral adipose tissue accumulation to total body fatness. Am. J. Clin. Nutr. 58 (1993) 463-467
50. Kashireddy P.R., and Rao M.S. Sex differences in choline-deficient diet-induced steatohepatitis in mice. Exp. Biol. Med. (Maywood) 229 (2004) 158-162
51. Kirsch R., Clarkson V., Shephard E.G., Marais D.A., Jaffer M.A., Woodburne V.E., Kirsch R.E., and Hall P.L. Rodent nutritional model of non-alcoholic steatohepatitis: species, strain and sex difference studies. J. Gastroenterol. Hepatol. 18 (2003) 1272-1282
52. Marques-Vidal P., Mazoyer E., Bongard V., Gourdy P., Ruidavets J.B., Drouet L., and Ferrieres J. Prevalence of insulin resistance syndrome in southwestern France and its relationship with inflammatory and hemostatic markers. Diabetes Care 25 (2002) 1371-1377
53. Arun J., Clements R.H., Lazenby A.J., Leeth R.R., and Abrams G.A. The prevalence of nonalcoholic steatohepatitis is greater in morbidly obese men compared to women. Obes. Surg. 16 (2006) 1351-1358
54. Lavine J.E., and Schwimmer J.B. Nonalcoholic fatty liver disease in the pediatric population. Clin. Liver Dis. 8 (2004) 549-5ix
55. Yatsuji S., Hashimoto E., Tobari M., Tokushige K., and Shiratori K. Influence of age and gender in Japanese patients with non-alcoholic steatohepatitis. Hepatol. Res. 37 (2007) 1034-1043
56. Jin X., Yu C.H., Lv G.C., and Li Y.M. Increased intestinal permeability in pathogenesis and progress of nonalcoholic steatohepatitis in rats. World J. Gastroenterol. 13 (2007) 1732-1736
57. Brun P., Castagliuolo I., Di L.V., Buda A., Pinzani M., Palu' G., and Martines D. Increased intestinal permeability in obese mice: new evidences in the pathogenesis of nonalcoholic steatohepatitis. Am. J. Physiol. Gastrointest. Liver Physiol. (2006)
58. Rivera C.A., Adegboyega P., van R.N., Tagalicud A., Allman M., and Wallace M. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J. Hepatol. 47 (2007) 571-579
59. Kirsch R., Clarkson V., Verdonk R.C., Marais A.D., Shephard E.G., Ryffel B., and de la M.H. Rodent nutritional model of steatohepatitis: effects of endotoxin (lipopolysaccharide) and tumor necrosis factor alpha deficiency. J. Gastroenterol. Hepatol. 21 (2006) 174-182
60. Yang S., Lin H., and Diehl A.M. Fatty liver vulnerability to endotoxin-induced damage despite NF-kappaB induction and inhibited caspase 3 activation. Am. J. Physiol. Gastrointest. Liver Physiol. 281 (2001) G382-G392
61. Li Z., Yang S., Lin H., Huang J., Watkins P.A., Moser A.B., Desimone C., Song X.Y., and Diehl A.M. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 37 (2003) 343-350
62. Wigg A.J., Roberts-Thomson I.C., Dymock R.B., McCarthy P.J., Grose R.H., and Cummins A.G. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 48 (2001) 206-211
63. Ruiz A.G., Casafont F., Crespo J., Cayon A., Mayorga M., Estebanez A., Fernadez-Escalante J.C., and Pons-Romero F. Lipopolysaccharide-binding protein plasma levels and liver TNF-alpha gene expression in obese patients: evidence for the potential role of endotoxin in the pathogenesis of non-alcoholic steatohepatitis. Obes. Surg. 17 (2007) 1374-1380
64. Wright S.D., Ramos R.A., Tobias P.S., Ulevitch R.J., and Mathison J.C. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 249 (1990) 1431-1433
65. Szabo G., Velayudham A., Romics Jr. L., and Mandrekar P. Modulation of non-alcoholic steatohepatitis by pattern recognition receptors in mice: the role of toll-like receptors 2 and 4. Alcohol Clin. Exp. Res. 29 (2005) 140S-145S
66. Tsukumo D.M., Carvalho-Filho M.A., Carvalheira J.B., Prada P.O., Hirabara S.M., Schenka A.A., Araujo E.P., Vassallo J., Curi R., Velloso L.A., and Saad M.J. Loss-of-function mutation in Toll-like receptor 4 prevents diet-induced obesity and insulin resistance. Diabetes 56 (2007) 1986-1998
67. Suganami T., Tanimoto-Koyama K., Nishida J., Itoh M., Yuan X., Mizuarai S., Kotani H., Yamaoka S., Miyake K., Aoe S., Kamei Y., and Ogawa Y. Role of the Toll-like receptor 4/NF-kappaB pathway in saturated fatty acid-induced inflammatory changes in the interaction between adipocytes and macrophages. Arterioscler. Thromb. Vasc. Biol. 27 (2007) 84-91
68. Lee J.Y., Sohn K.H., Rhee S.H., and Hwang D. Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through Toll-like receptor 4. J. Biol. Chem. 276 (2001) 16683-16689
69. Shi H., Kokoeva M.V., Inouye K., Tzameli I., Yin H., and Flier J.S. TLR4 links innate immunity and fatty acid-induced insulin resistance. J. Clin. Invest. 116 (2006) 3015-3025